biologics
Green Cross Biologics To Enter Russian Market
A partnership with Russian pharmaceutical Nanolek sees Green Cross' biologics enter the rapidly growing Russian market.
Innovent Raises US$100 Million
Supported by the latest round of funding, Innovent will open China's largest internationally certified biologics production facility.
Baxter Expands Biologics In Singapore
Baxter's biologic facility in Singapore has been approved by the European Medicines Agency to supply products for hemophiliacs.
A*STAR & Roche Develop Cancer Killing Antibodies
Scientists have developed a new approach to cancer treatment: using antibodies which can target and directly kill cancer cells.
Eisai & KRI Open New Research Facility In Kobe
The new facility located in the Kansai International Strategic Innovation Zone will focus on developing biologic therapies.
WuXi Completes Biosafety Facility In Suzhou
Continuing with its rapid expansion of manufacturing capabilities, WuXi completes a new 38,000 square foot facility in Suzhou.
WuXi Begins Construction Of New Facility In Philadelphia
WuXi PharmaTech's intended 45,000 square feet facility will be for the manufacture of cell-based therapeutics.
Green Cross Expands Biologics To North America
The proposed US$163 million Green Cross facility will have the capacity to fractionate up to one million liters of plasma a year.
Agilent, University Of Rouen, A*STAR To Collaborate In Glycomics
Agilent, the University of Rouen, and A*STAR have signed an MOU to develop tools to effectively analyze biologics and vaccines.
